SCHEMBL21710490

SCHEMBL21710490

c1ccc2c(c1)cc1c3ccccc3n3c4ccccc4c2c13

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 5/20 0.40
ALDH1A1 P00352 4/20 0.40
HIF1A Q16665 2/20 0.40
CYP1B1 Q16678 1/20 0.40
KMT2A Q03164 3/20 0.37
CASP1 P29466 2/20 0.37
GAA P10253 2/20 0.37
PKM P14618 1/20 0.37
GALK1 P51570 1/20 0.37
BLM P54132 1/20 0.37
CASP7 P55210 1/20 0.37
SAE1 Q9UBE0 1/20 0.37
UBA2 Q9UBT2 1/20 0.37
CDC25B P30305 1/20 0.36
GPR3 P46089 1/20 0.35
CYP1A2 P05177 3/20 0.35
CYP2A6 P11509 1/20 0.35
KDM4E B2RXH2 5/20 0.35
HPGD P15428 3/20 0.35
SMN1; SMN2 Q16637 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20857867 0.93 HSD17B10 (0.38) HSD17B10ALDH1A1HIF1ACYP1B1KMT2A
SCHEMBL20857845 0.93 HSD17B10 (0.38) HSD17B10ALDH1A1HIF1ACYP1B1KMT2A
SCHEMBL24026871 0.92 HSD17B10 (0.34) HSD17B10ALDH1A1HIF1ACYP1B1KMT2A
SCHEMBL24026869 0.91 HSD17B10 (0.36) HSD17B10ALDH1A1HIF1ACYP1B1KMT2A
SCHEMBL24026873 0.91 HSD17B10 (0.36) HSD17B10ALDH1A1HIF1ACYP1B1KMT2A
SCHEMBL22868315 0.88 HSD17B10 (0.34) HSD17B10ALDH1A1HIF1ACYP1B1KMT2A
SCHEMBL26261160 0.87 HSD17B10 (0.41) HSD17B10ALDH1A1HIF1ACYP1B1CASP1
SCHEMBL21717842 0.86 KDM4E (0.40) HSD17B10ALDH1A1HIF1ACYP1B1KMT2A
SCHEMBL21718132 0.85 CYP2A6 (0.40) HSD17B10ALDH1A1HIF1ACYP1B1KMT2A
SCHEMBL21710699 0.85 CYP2A6 (0.40) HSD17B10ALDH1A1HIF1ACYP1B1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230286989-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2023-09-14 US disclosed
US-20230286989-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES UNIVERSAL DISPLAY CORPORATION (US) 2023-09-14 US disclosed
US-11723272-B2 Organic electroluminescence element and electronic device IDEMITSU KOSAN CO., LTD. (JP) 2023-08-08 US disclosed
US-11723272-B2 Organic electroluminescence element and electronic device IDEMITSU KOSAN CO., LTD. (JP) 2023-08-08 US disclosed
US-20210005826-A1 ORGANIC ELECTROLUMINESCENCE ELEMENT AND ELECTRONIC APPARATUS IDEMITSU KOSAN CO., LTD. (JP) 2021-01-07 US disclosed
US-20210005825-A1 ORGANIC ELECTROLUMINESCENT ELEMENT AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2021-01-07 US disclosed
US-20200365812-A1 ORGANIC ELECTROLUMINESCENCE ELEMENT AND ELECTRONIC DEVICE IDEMITSU KOSAN CO.,LTD. (JP) 2020-11-19 US disclosed
US-20200052212-A1 ORGANIC ELECTROLUMINESCENT ELEMENT AND ELECTRONIC DEVICE IDEMITSU KOSAN CO., LTD. (JP) 2020-02-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210005825-A1 ORGANIC ELECTROLUMINESCENT ELEMENT AND ELECTRONIC DEVICE OR51E2, CD99, CTNND1 HSD17B10 1426/4885ALDH1A1 37/4885HIF1A 3749/4885
US-20230286989-A1 ORGANIC ELECTROLUMINESCENT MATERIALS AND DEVICES OCIAD2, OCIAD1, ODC1 HSD17B10 1099/4885ALDH1A1 160/4885HIF1A 4869/4885
US-20210005826-A1 ORGANIC ELECTROLUMINESCENCE ELEMENT AND ELECTRONIC APPARATUS EML4, EBPL, LEF1 HSD17B10 1793/4885ALDH1A1 189/4885HIF1A 4752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.